I guess this story(see below) doesn't mean anything to PLC? IMO PLC is a great value play right now. The turnaround on the balance sheet started last quarter and should continue. I would like to find some investors to buy the whole company and run it the right way. The search for a new top man should stop with me...lol. I think I would do a much better job that Dow ever did and I don't studder when I speak, especially on conference calls.
Hold strong, someone will see what we see in PLC.
Regards,
Rob
This Week's 'The Lancet' Reports Eclipse TMR Is an Effective TreatmentFor Angina
SUNNYVALE, Calif, Sept. 14 /PRNewswire/ -- Eclipse Surgical Technologies, Inc. (Nasdaq: ESTI) announced that the British medical journal "The Lancet" reported results from a study of TMR, which showed improved exercise time, lower angina scores and improved quality of life in patients with severe angina resulting from advanced coronary artery disease that is not suitable for bypass surgery or angioplasty.
"We want to thank the investigators for their contributions to this rigorous and important clinical study. The study, which we refer to as the ATLANTIC study, provides insightful data on the clinical merits of TMR for the treatment of patients who have no therapeutic option for their severe coronary artery disease. We believe this information will have a positive impact on physicians considering TMR for their patients," said Allen W. Hill, President & CEO of Eclipse.
The study was presented in the September 11, 1999 edition of "The Lancet." Additional information can be obtained thelancet.com .
Eclipse is the leading medical device company specializing in Transmyocardial Revascularization. The Company currently manufactures and markets the Eclipse TMR 2000, a solid-state Holmium:YAG laser system, as well as the Eclipse SoloGrip II, a surgical handpiece with built-in laser fiberoptics and other TMR products. TMR is a laser based heart treatment in which one millimeter channels are created in the heart muscle. These channels are believed to stimulate the growth of new blood vessels (angiogenesis). TMR has been shown to reduce angina, improve functional capacity and improve the quality of life for patients suffering with coronary artery disease.
Percutaneous TMR (PTMR) is a minimally invasive approach to TMR performed in a cardiac catherization lab by a cardiologist. PTMR products are investigational devices in the U.S. and the procedure is currently the subject of ongoing clinical trials.
The forward-looking statements in this news release related to TMR are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause the actual results to differ materially. Other factors that could cause Eclipse's actual results to differ materially include uncertainties associated with clinical trials, no assurance of market acceptance, regulatory approvals, potential third-party patent infringement claims as well as additional risk factors, as discussed in the "Risk Factors" section of Eclipse's Annual Report on Form 10-K dated December 31, 1998, and Eclipse's quarterly reports filed with the U.S. Securities and Exchange Commission (SEC).
For more information on the Company and its products, please visit the Eclipse Web site at eclipsesurg.com .
SOURCE Eclipse Surgical Technologies, Inc.
CO: Eclipse Surgical Technologies, Inc.
ST: California
IN: BIO MTC
SU:
09/14/1999 18:41 EDT prnewswire.com |
